Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sami Shousha

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Breast Cancer Research and Treatment|March 26, 2017
Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancerMuhammad Asaduzzaman, Stephanie Constantinou, Haoxiang Min, et al.
Breast Cancer Research and Treatment|January 7, 2018
Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancerMuhammad Asaduzzaman, Stephanie Constantinou, Haoxiang Min, et al.
Physics in Medicine and Biology|January 15, 2010
Kinetic filtering of [(18)F]Fluorothymidine in positron emission tomography studiesKatherine R Gray, Kaiyumars B Contractor, Laura M Kenny, et al.
Nuclear Medicine Communications|August 25, 2011
Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomographyKaiyumars B Contractor, Laura M Kenny, Justin Stebbing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
[11C]choline positron emission tomography in estrogen receptor-positive breast cancerKaiyumars B Contractor, Laura M Kenny, Justin Stebbing, et al.
Breast Cancer Research : BCR|May 25, 2017
Rapid evaporative ionisation mass spectrometry of electrosurgical vapours for the identification of breast pathology: towards an intelligent knife for breast cancer surgeryEdward R St John, Julia Balog, James S McKenzie, et al.
Clinical Breast Cancer|May 17, 2011
Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab eraCarlo Palmieri, Deep Shah, Jonathan Krell, et al.
The Lancet. Oncology|June 1, 2005
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trialAndreas Polychronis, H Dudley Sinnett, Dimitri Hadjiminas, et al.
International Journal of Oncology|June 11, 2009
FoxM1 is a downstream target and marker of HER2 overexpression in breast cancerRichard E Francis, Stephen S Myatt, Janna Krol, et al.
Nature Communications|August 21, 2019
Author Correction: SREBP1 drives keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancerYlenia Perone, Aaron J Farrugia, Alba Rodríguez-Meira, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Breast Cancer Research and Treatment|March 26, 2017
Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancerMuhammad Asaduzzaman, Stephanie Constantinou, Haoxiang Min, et al.
Breast Cancer Research and Treatment|January 7, 2018
Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancerMuhammad Asaduzzaman, Stephanie Constantinou, Haoxiang Min, et al.
Physics in Medicine and Biology|January 15, 2010
Kinetic filtering of [(18)F]Fluorothymidine in positron emission tomography studiesKatherine R Gray, Kaiyumars B Contractor, Laura M Kenny, et al.
Nuclear Medicine Communications|August 25, 2011
Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomographyKaiyumars B Contractor, Laura M Kenny, Justin Stebbing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
[11C]choline positron emission tomography in estrogen receptor-positive breast cancerKaiyumars B Contractor, Laura M Kenny, Justin Stebbing, et al.
Breast Cancer Research : BCR|May 25, 2017
Rapid evaporative ionisation mass spectrometry of electrosurgical vapours for the identification of breast pathology: towards an intelligent knife for breast cancer surgeryEdward R St John, Julia Balog, James S McKenzie, et al.
Clinical Breast Cancer|May 17, 2011
Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab eraCarlo Palmieri, Deep Shah, Jonathan Krell, et al.
The Lancet. Oncology|June 1, 2005
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trialAndreas Polychronis, H Dudley Sinnett, Dimitri Hadjiminas, et al.
International Journal of Oncology|June 11, 2009
FoxM1 is a downstream target and marker of HER2 overexpression in breast cancerRichard E Francis, Stephen S Myatt, Janna Krol, et al.
Nature Communications|August 21, 2019
Author Correction: SREBP1 drives keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancerYlenia Perone, Aaron J Farrugia, Alba Rodríguez-Meira, et al.
Pageof 6